IRIS
CAVESTRO, Giulia Martina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.506
AS - Asia 4.174
EU - Europa 3.325
SA - Sud America 682
AF - Africa 270
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 13.970
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.334
SG - Singapore 1.785
CN - Cina 1.413
SE - Svezia 649
IE - Irlanda 619
UA - Ucraina 528
BR - Brasile 519
FI - Finlandia 433
DE - Germania 404
HK - Hong Kong 319
VN - Vietnam 252
TR - Turchia 210
ZA - Sudafrica 180
NL - Olanda 169
IT - Italia 140
GB - Regno Unito 123
CA - Canada 112
RU - Federazione Russa 94
AR - Argentina 70
CI - Costa d'Avorio 54
IN - India 39
MX - Messico 36
FR - Francia 35
BD - Bangladesh 28
BE - Belgio 24
EC - Ecuador 19
PL - Polonia 19
IQ - Iraq 18
LT - Lituania 18
CO - Colombia 17
ES - Italia 14
PE - Perù 14
IR - Iran 13
PY - Paraguay 13
UZ - Uzbekistan 13
JP - Giappone 11
RO - Romania 10
CL - Cile 9
PK - Pakistan 9
VE - Venezuela 9
CZ - Repubblica Ceca 8
ID - Indonesia 8
KE - Kenya 8
AT - Austria 7
AZ - Azerbaigian 7
EG - Egitto 7
EU - Europa 7
MA - Marocco 7
PA - Panama 6
TN - Tunisia 6
UY - Uruguay 6
BO - Bolivia 5
GT - Guatemala 5
IL - Israele 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
GE - Georgia 4
JO - Giordania 4
MD - Moldavia 4
RS - Serbia 4
AL - Albania 3
AU - Australia 3
BG - Bulgaria 3
BN - Brunei Darussalam 3
HU - Ungheria 3
NO - Norvegia 3
PH - Filippine 3
SA - Arabia Saudita 3
AM - Armenia 2
DZ - Algeria 2
HN - Honduras 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
PS - Palestinian Territory 2
PT - Portogallo 2
TJ - Tagikistan 2
TT - Trinidad e Tobago 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GI - Gibilterra 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
MU - Mauritius 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
Totale 13.959
Salva come PNG Salva come JPEG
Città #
Chandler 859
Singapore 802
Dublin 616
Jacksonville 538
Ashburn 510
Santa Clara 483
Dearborn 401
Hong Kong 315
Beijing 279
Nanjing 252
Boardman 228
Izmir 174
Johannesburg 172
Dallas 157
Princeton 154
San Mateo 147
Ann Arbor 122
Ho Chi Minh City 118
Shanghai 114
Munich 105
New York 90
Shenyang 84
Toronto 82
Wilmington 81
Los Angeles 72
Helsinki 68
Moscow 68
Nanchang 60
Abidjan 54
Hebei 53
São Paulo 49
Kunming 47
Tianjin 45
Changsha 42
Hanoi 41
Hefei 40
Jiaxing 39
Jinan 39
Buffalo 35
Turku 30
Norwalk 29
Kocaeli 26
Woodbridge 26
Parma 25
Brussels 23
Frankfurt am Main 22
Guangzhou 22
Houston 20
Hangzhou 19
Zhengzhou 19
Des Moines 18
Columbus 17
Pune 16
Taranto 16
Stockholm 15
Warsaw 15
Council Bluffs 14
Montreal 14
Seattle 14
Grafing 13
London 13
Rio de Janeiro 13
Boston 12
Chicago 12
Denver 12
Belo Horizonte 11
Brasília 11
Bremen 11
Cambridge 11
Hải Dương 11
Lima 11
Ningbo 11
Phoenix 11
Tashkent 11
Brooklyn 10
Porto Alegre 10
Auburn Hills 9
Curitiba 9
San Francisco 9
Fortaleza 8
Messina 8
Poplar 8
Quito 8
Atlanta 7
Bari 7
Da Nang 7
Leawood 7
Nairobi 7
Nuremberg 7
Orem 7
Rio Saliceto 7
San Gregorio di Catania 7
Tokyo 7
Baku 6
Campina Grande 6
Chengdu 6
Düsseldorf 6
Fremont 6
Haikou 6
Manaus 6
Totale 8.400
Salva come PNG Salva come JPEG
Nome #
5 OP Keratin 8 gene mutation in patients with chronic pancreatitis 190
A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? 145
W1079 Curcumin Vs Domperidon in Functional Dyspepsia: Better the Prokinetic or An Agonist of Vanilloid Receptor? 143
Associations of spink-1 (N345) and PRSS-1 (N29I AND R122H) gene mutations and chronic pancreatitis in Italy 141
710 Gastrin-17 (G-17): A Serological Bio-Marker for Diagnosis of Gastro-Esophageal Reflux Disease (GERD) 137
Autonomic balance in inflammatory bowel diseases, irritable bowel syndrome and gastroesophageal reflux disease 135
7 P Frequency of CFTR gene mutations in consecutive patients suffering from chronic pancreatitis 133
42 OP Potential use of lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: A pilot study 132
Accuracy of “serological gastric biopsy” in a cohort of dyspeptic patients 129
Association of HLA-DRB1 *0401 Allele with chronic pancreatitis 129
Association of keratin 8 gene mutation with chronic pancreatitis 127
T1082 Eradication Rate of Helicobacter pylori in Immigrant Patients Compared to Italian Patients: Results of a Clinical Trial 127
S1921 “GastroPanel Test” in the Clinical Outcome of GERD 126
Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment? 125
Clinical Trends and Burden of Death in Gastric Cancer: A Six Years Survey 125
P.08.9: The Early Diagnosis of Gastric Cancer: A Six Years Survey Based on 584 Surgical Specimen in Parma Area 125
Serum pepsinogen II for early assessment of success of H. pylori eradication 125
S1808 Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR and SPINK-1 in the Clinical Setting of Acute, Acute Recurrent and Chronic Pancreatitis 123
P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY 122
Bovine lactoferrin as a rescure treatment for Helicobacter pylori infection: results of a multicenter study 121
P.29 USEFULNESS OF NON INVASIVE TEST (GASTROPANEL) FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE 119
P.154 CONNECTIONS BETWEEN GENETICS AND CLINICAL DATA: ROLE OF MCP-1, CFTR, AND SPINK-1 IN THE SETTING OF ACUTE, ACUTE RECURRENT, AND CHRONIC PANCREATITIS 118
OC1.09.3 USEFULNESS OF GASTROPANEL FOR SCREENING OF ATROPHIC GASTRITIS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASES 118
Rabepmzole in the treatment of non-responders GERD patients: a prospective six-month study 118
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 117
Associations of Spink-1 (N34S) and PRSS-1 (N29I and R122H) gene mutations and chronic pancreatitis in Italy 116
Usefulness of Serum Pepsinogens to Identify Chronic Atrophic Gastritis 116
Gastro panel® for detection of atrophic gastritis: The “Parma model” 116
Esophagitis: acute therapy with omeprazole (Single Dosage Versus BID) 115
Gastrin-17 (G-17) as a sensitive serological bio-marker for diagnosis of gastro-esophageal reflux disease (GERD) independently of H. pylori status 114
T1651 The Natural History of Gastric Ulcer: A Twenty-Four Years Clinical-Endoscopical Follow-Up 113
PA.6 GASTRIN-17 (G-17): A SEROLOGICAL BIO-MARKER FOR DIAGNOSIS OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) 113
Gastroesophageal reflux disease in celiac patients: Preliminary results in 35 consecutive patients 111
OC3.07.1 CURCUMIN VS DOMPERIDON IN FUNCTIONAL DYSPEPSIA: BETTER THE PROKINETIC OR AN AGONIST OF VANILLOID RECEPTOR? 111
Pepsinogen I, II, Ratio, and G-17 in Patients With Esophagitis and Patients With Extra-Esophageal Manifestations of GERD 111
A prospective therapeutical one-year study with pantoprazole for patients with oropharingeal picture of GERD 109
M1141 Diagnostic Accuracy of Serum Pepsinogens and Gastrin to Follow-up Helicobacter pylori Infection: A Pilot Study 109
Lactoferrin in a 1-week triple therapy for eradication of H. pylori 108
PA.7 CLINICAL VARIABILITY IN THE PRESENTATION OF THE GASTROESOPHAGEAL REFLUX DISEASE BEFORE THE HP ERA (STUDY FROM 1975 TO 1995) 108
M1260 Effect of Cyclically Long-Term Treatment With Mesalamine in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD): A 5 Years Follow-up Study 107
PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS 107
A new marker for monitoring alcohol abuse? A pilot study on heavy drinkers 106
Usefulness of a serological panel test in the assessment of gastritis in symptomatic children 105
P.10 “GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD: PROSPECTIVE SIX MONTHS CLINICAL STUDY 102
Chronic atrophic gastritis (GAC) and Helicobacter pylori infection eradication: a 3 years follow-up 101
LONG-TERM TREATMENT WITH MESALAMINE IN DIVERTICULAR DISEASE: A FIVE YEARS FOLLOW-UP STUDY 101
P.1.292: SYMPTOMATOLOGICAL PATTERN IN PATIENTS WITH SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE (SUDD), IRRITABLE BOWEL SYNDROME-DIARRHOEA (IBS-D), AND IBS-D PLUS SUDD 101
M1262 Baseline Symptoms in Patients With Symptomatic Uncomplicated Diverticular Disease (SUDD) 101
Are there useful biomarkers for gastric cancer? 100
Hypercalcemia due to ectopic secretion of parathyriod related protein from pancreatic carcinoma: a case report 100
Disappearance of gallbladder wall lesions after treatment with ursodeozycolic acid 100
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis 99
A new curcumin-based one week therapy for eradication of H. pylori infection 99
“GASTROPANEL TEST” IN THE CLINICAL OUTCOME OF GERD 98
Topography of gastric damage in H.pylori infection: evaluation by serum pepsinogens levels 97
Low alcohol and cigarette use is associated to the risk of developing chronic pancreatitis 97
Study design biases in pancreatic inflammatory diseases. 96
DO PREBIOTICS RELIEVE CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-C) SYMPTOMS? A RANDOMIZED SINGLE BLINDED STUDY 95
Clinical and radiological outcome of patients suffering from chronic pancreatitis associated with gene mutations. 95
Usefullness of gastropanel in different topography of H. pylori related chronic gastritis 94
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. 94
Natural course of functional dyspepsia after after helicobacter pylori eradication a 7-year survey 93
P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROP H IC GASTRITIS 93
CORRELATION BETWEEN LACTOSE H2-BREATH TEST AND CLINICAL DATA: IS IT POSSIBLE TO SELECT PATIENTS WHO NEED LACTOSE BREATH TEST? 93
Recovery of gastric function after H. pylori eradication in subjects with body atrophic gastritis: a prospective four years study 92
Quality of life in patients with chronic pancreatitis 91
Lactoferrin: mechanism of action, clinical significance and therapeutic 91
Prevalence of H. pylori CagA+ve in suburban area with high incidence of gastric cancer 91
PANCREATIC PSEUDOCYSTS FOLLOWING ACUTE PANCREATITIS: RISK FACTORS INFLUENCING THERAPEUTIC OUTCOMES 91
Efficacy of mesalazine in the treatment of symptomatic diverticular disease 90
Italian consensus guideline for chronic pancreatitis. 90
Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update 90
Serum pepsinogen II and gastrin-17 as markers of NSAIDs gastropathy 90
Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels 89
Gastroprotective effects of Amtolmetin Guacyl: a new non steroidal antiinflammatory drug that activates inducible gastric niytric oxide synthase 89
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population 88
Recovery of gastric function after Helicobacter pylori eradication in subjects with body atrophic gastritis: prospective 4-year study 87
Nonteroidal drug-related gastroduodenal damage in the elderly 86
Rabeprazole for the treatment of oropharingeal picture of GERD: a six-month prospective study 85
Lactoferrin in a one week triple therapy for eradication of H. Pylori 85
Assessment of H. pylori-related chronic gastritis by means of serum pepsinogens and oral sucrose 85
Serum pepsinogen II as a biomarker in management of H. pylori infection 85
Gastropanel as screening of gastric atrophy in primary care 84
Clinical usefulness of serum pepsinogen II in the assessment of H. pylori infection 84
HLA-DRB1*04 Allele contribute to the genetic susceptibility of chronic pancreatitis 84
Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. 84
Serum pepsinogen II and Gastrin-17 (G-17) as markers of NSAIDS gastropathy 83
Diagnosis of H. pylori gastritis patterns by means of gastropanel 83
Therapy of NERD: single Vs double rabeprazole dosage 83
TAP genes, coding for the transporters associated with antigen processing, contribute to the genetic predisposition to primary sclerosing cholangitis (PSC) 83
Fisiopatologia pancreatica 82
Macrohematuria caused by a fall in prothrombin activity as a clinical presentation of celiac disease. (I.F. 1.357) 82
Relationship between direct and indirect methods for diagnosis of H.pylori infection 81
Hyperbilirubinemia: does it matter? 81
Clinical usefulness of Gastropanel (SPGI, SPGII, GASTRIN-17, HP SPECIFIC IgG) in the assessment of HP infection 80
‘Serological Biopsy’ in first degree relatives of patients with gastric cancer, affected by Helicobacter pylori 80
THE SIZE OF PANCREATIC PSEUDOCYST DOES NOT INFLUENCE THE OUTCOME OF INVASIVE TREATMENTS 80
Lactoferrin in a 7 days triple therapy for helicobacter pylori eradication: results of an open randomized trial 79
GENETICS OF CHRONIC PANCREATITIS 79
Rabeprazole in the treatment of non-responders GERD patients: a prospective six-month study 79
Totale 10.360
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021483 0 0 0 0 0 8 108 5 189 32 133 8
2021/2022777 14 15 10 36 43 17 80 108 32 87 92 243
2022/20232.618 294 253 169 234 238 325 7 188 797 9 81 23
2023/2024784 53 84 24 22 56 217 40 61 18 48 77 84
2024/20253.030 83 187 214 148 364 356 36 142 452 286 219 543
2025/20262.992 515 523 519 542 853 40 0 0 0 0 0 0
Totale 14.029